Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) Equity Income (2023 - 2025)

Rallybio's Equity Income history spans 3 years, with the latest figure at -$287000.0 for Q2 2025.

  • For Q2 2025, Equity Income rose 41.07% year-over-year to -$287000.0; the TTM value through Sep 2025 reached -$1.3 million, up 46.16%, while the annual FY2024 figure was -$2.2 million, 9.7% down from the prior year.
  • Equity Income for Q2 2025 was -$287000.0 at Rallybio, up from -$587000.0 in the prior quarter.
  • Across five years, Equity Income topped out at -$217000.0 in Q2 2023 and bottomed at -$685000.0 in Q1 2024.
  • The 3-year median for Equity Income is -$575000.0 (2023), against an average of -$515400.0.
  • The largest annual shift saw Equity Income tumbled 124.42% in 2024 before it skyrocketed 41.07% in 2025.
  • A 3-year view of Equity Income shows it stood at -$613000.0 in 2023, then increased by 29.85% to -$430000.0 in 2024, then soared by 33.26% to -$287000.0 in 2025.
  • Per Business Quant, the three most recent readings for RLYB's Equity Income are -$287000.0 (Q2 2025), -$587000.0 (Q1 2025), and -$430000.0 (Q4 2024).